Kato Ladies Clinic, 7-20-3 Nishishinjyuku, Shinjyuku-ku, Tokyo, 160-0023, Japan.
BMC Pregnancy Childbirth. 2024 May 4;24(1):343. doi: 10.1186/s12884-024-06546-4.
Vitrification procedures decrease intracytoplasmic lipid content and impair developmental competence. Adding fatty acids (FAs) to the warming solution has been shown to recover the lipid content of the cytoplasm and improve developmental competence and pregnancy outcomes. However, the influence of the FA supplementation on live birth rates after embryo transfers and perinatal outcomes remains unknown. In the present study, we examined the influence of FA-supplemented warming solutions on live birth rates, pregnancy complications, and neonatal outcomes after single vitrified-warmed cleavage-stage embryo transfers (SVCTs).
The clinical records of 701 treatment cycles in 701 women who underwent SVCTs were retrospectively analyzed. Vitrified embryos were warmed using solutions (from April 2022 to June 2022, control group) or FA-supplemented solutions (from July 2022 to September 2022, FA group). The live birth rate, pregnancy complications, and perinatal outcomes were compared between the control and FA groups.
The live birth rate per transfer was significantly higher in the FA group than in the control group. Multivariate logistic regression analysis further demonstrated a higher probability of live births in the FA group than in the control group. Miscarriage rates, the incidence and types of pregnancy complications, the cesarean section rate, gestational age, incidence of preterm delivery, birth length and weight, incidence of low birth weight, infant sex, and incidence of birth defects were all comparable between the control and FA groups. Multivariate logistic regression analysis further demonstrated no adverse effects of FA-supplemented warming solutions.
FA-supplemented warming solutions improved live birth rates after SVCTs without exerting any adverse effects on maternal and obstetric outcomes. Therefore, FA-supplemented solutions can be considered safe and effective for improving clinical outcomes and reducing patient burden.
玻璃化程序会降低细胞质内的脂质含量，并损害发育能力。向解冻液中添加脂肪酸（FA）已被证明可以恢复细胞质的脂质含量，提高发育能力和妊娠结局。然而，FA 补充对胚胎移植后的活产率和围产期结局的影响尚不清楚。在本研究中，我们研究了 FA 补充的解冻液对卵裂期胚胎玻璃化解冻后单胚胎移植（SVCT）的活产率、妊娠并发症和新生儿结局的影响。
回顾性分析了 701 名妇女 701 个治疗周期的临床记录，这些妇女接受了 SVCT。使用溶液（2022 年 4 月至 2022 年 6 月，对照组）或 FA 补充溶液（2022 年 7 月至 2022 年 9 月，FA 组）解冻玻璃化胚胎。比较对照组和 FA 组的活产率、妊娠并发症和围产期结局。
FA 组的每移植活产率显著高于对照组。多变量逻辑回归分析进一步表明，FA 组的活产率高于对照组。流产率、妊娠并发症的发生率和类型、剖宫产率、胎龄、早产发生率、出生长度和体重、低出生体重发生率、婴儿性别和出生缺陷发生率在对照组和 FA 组之间均无差异。多变量逻辑回归分析进一步表明，FA 补充的解冻液没有不良影响。
FA 补充的解冻液提高了 SVCT 后的活产率，而对母婴结局没有任何不良影响。因此，FA 补充的溶液可以被认为是安全有效的，可改善临床结局并减轻患者负担。
